Solomon Moshkevich Sells 24,861 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of Natera stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the sale, the insider now owns 140,684 shares of the company’s stock, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.

Natera Stock Performance

NTRA stock opened at $167.61 on Friday. The company has a 50-day simple moving average of $166.20 and a 200 day simple moving average of $136.25. The company has a market capitalization of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $62.96 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the firm posted ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis. Sell-side analysts predict that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several hedge funds have recently modified their holdings of the company. Covestor Ltd lifted its holdings in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Blue Trust Inc. lifted its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the last quarter. Hanseatic Management Services Inc. grew its stake in shares of Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock worth $158,000 after purchasing an additional 107 shares during the last quarter. Finally, Salem Investment Counselors Inc. grew its stake in shares of Natera by 0.7% in the 4th quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock worth $2,577,000 after purchasing an additional 110 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the topic of several research reports. Craig Hallum upped their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group raised their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Piper Sandler boosted their price objective on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Morgan Stanley raised their target price on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, Robert W. Baird upped their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.